CDC Anthrax Vaccine Clinical Trial

• ClinicalTrials.gov Identifier: NCT00119067
• Recruitment Status: Completed
• First Posted: July 13, 2005
• Last Update Posted: February 26, 2014
• Sponsor: Centers for Disease Control and Prevention
• Collaborators: Walter Reed Army Institute of Research (WRAIR); Baylor College of Medicine; University of Alabama at Birmingham; Emory University; Mayo Clinic
• Information provided by (Responsible Party): Centers for Disease Control and Prevention

Study Description

Brief Summary:

Anthrax Clinical Trial Objectives:

To assess whether:

• Anthrax vaccine (AVA or BioThrax, BioPort Corp. Lansing MI) administered by the intramuscular (IM) route elicits antibody responses that are not inferior (i.e., "non-inferior") to that achieved by the currently licensed schedule.
• BioThrax administered by the IM route and containing fewer numbers of doses elicits antibody responses that are not inferior (i.e., "non-inferior") to that achieved by the currently licensed schedule.
• Differences in reactogenicity exist between the IM and subcutaneous (SQ) administration of BioThrax.

Additionally for the final report we will assess whether:

• Occurrence of adverse events following AVA administration is influenced by selected risk factors.

Condition or disease	Intervention/treatment	Phase
Healthy	Biological: BioThrax or Anthrax Vaccine Adsorbed	Phase 4

Detailed Description:

This study is a 43-month prospective, randomized, double-blind, placebo-controlled comparison of immunogenicity and reactogenicity elicited by BioThrax given by different routes of administration (SQ versus IM) and dosing regimens (as many as 8 doses versus as few as 4 doses). Sterile saline is used as the placebo where doses are dropped in regimens using AVA, and in the all-placebo study group.

This study is conducted among a total of 1564 healthy adult men and women (18 to 61 years of age) at five sites in the United States. Participants were randomized into one of 6 study groups with 260 participants per group. One group receives BioThrax given as currently licensed (SQ with 6 doses followed by annual boosters); another group is given placebo IM (130 participants) or SQ (130 participants) in the currently licensed dosing regimen. The four other groups receive BioThrax IM in modified dosing regimens; placebo is given when a dose of BioThrax is omitted from the licensed dosing regimen. There are a total of 25 required visits for this study, during which all participants receive an injection of vaccine or placebo (8 injections total), have a blood sample drawn (16 or 17 total), and have an in-clinic examination for adverse events (22 total).

Immunogenicity is assessed by assaying 16 serial blood samples obtained from all participants and a 17th sample from a subset of participants before vaccination and at other specified times. Total anti-protective antigen IgG antibody (anti-PA IgG) is quantified using a standardized and validated enzyme-linked immunosorbent assay (ELISA); the primary study endpoints are 4-fold rise in antibody titer and antibody concentration relative to the pre-vaccination titers or assay reactivity threshold. A subset of serum samples is also assayed in an in vitro toxin neutralization assay (TNA) to measure the functional activity of anti-BioThrax antibodies. The kinetics of the immune response to BioThrax are examined at 3 time points in the study and blood samples from a subset of participants will be further tested in correlates of protection and immunogenetics substudies. All adverse events (AEs), including vaccine reactogenicity, are actively monitored. While all AEs will be ascertained among study participants, several endpoints will be defined based on the likelihood of their occurrence and/or their clinical importance. Of primary interest is the occurrence of local AEs such as warmth, tenderness, itching, pain, arm motion limitation, erythema, induration, nodule, and bruise. Systemic AEs such as fever, fatigue, muscle ache, headache, temperature, and painful axillary adenopathy are also evaluated.

This study is expected to provide the basis for consideration of change in route of BioThrax administration from SQ to IM and reduction in number of vaccine doses required for primary and booster immunization.

There is an interim analysis of data collected through each participant's first 7 months of this study for consideration in changing the route of BioThrax administration from SQ to IM, and elimination of the 2 week vaccine priming dose.

At the end of the study, the Sponsor will present the entire results of the trial to FDA for consideration in elimination of additional doses from the licensed BioThrax schedule. At that time, the Sponsor will also supplement these data with results from parallel non-human primate challenge studies and additional research on immunologic correlates of protection.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1560 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction
• Study Start Date: May 2002
• Actual Primary Completion Date: February 2010
• Actual Study Completion Date: February 2010

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: AVA 8-SQ; receive 8 injections of AVA SQ	Biological: BioThrax or Anthrax Vaccine Adsorbed
Experimental: AVA 8-IM; receive 8 injections of AVA IM	Biological: BioThrax or Anthrax Vaccine Adsorbed
Experimental: AVA 7-IM; receive 7 injections of AVA IM	Biological: BioThrax or Anthrax Vaccine Adsorbed
Experimental: AVA 5-IM; receive 5 injections of AVA IM	Biological: BioThrax or Anthrax Vaccine Adsorbed
Experimental: AVA 4-IM; receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42	Biological: BioThrax or Anthrax Vaccine Adsorbed
Placebo Comparator: Saline placebo IM or SQ

Outcome Measures

Primary Outcome Measures :

1. local AEs - warmth, tenderness, itching, pain, arm motion limitation, erythema, induration, nodule, and bruise [ Time Frame: completed ]
   no safety issues to assessing this
2. systemic AEs -fever, fatigue, muscle ache, headache, temperature, and painful axillary adenopathy [ Time Frame: completed ]
3. non-inferiority of anti-protective antigen IgG geometric mean concentration (GMC) of the study groups (8-SQ, 7-IM, 5-IM, 4-IM) to the 8-SQ group [ Time Frame: completed ]

Secondary Outcome Measures :

1. A subset (30%) samples are selected for toxin neutralization assay [ Time Frame: completed ]
2. the kinetics of the immune response to BioThrax are examined at 3 time points in the study [ Time Frame: completed ]
3. assessment of other immune humoral and cell mediated antibody responses [ Time Frame: ongoing ]
4. assessment of risk factors for adverse events [ Time Frame: ongoing ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 61 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Read and signed the Informed Consent Document
• Female or male, 18 to 61 years old (up to 62nd birthday)
• Females must agree to exercise adequate birth control from the time of the screening procedures to one month after the last vaccination
• Willingness and ability to return for all follow-up visits and blood collections for the duration of the study
• Ability to understand and comply with planned study procedures
• Agree to complete the Participant Diary (Appendix G) and to report concomitant medications and AEs during the study period
• Have two intact upper arms with sufficient subcutaneous and intramuscular tissue in the deltoid regions for vaccine administration.
• Potential participants with a history of the following conditions remain eligible for study enrollment: gestational diabetes; treated, controlled, uncomplicated hypertension; treated hypo- or hyperthyroidism; cured nonmetastatic cancer; disease-free for 5 years (excluding hematologic malignancies); localized skin cancer, resected (including squamous cell and basal cell carcinomas, participants with a history of melanoma must be disease-free for 5 years); exercise-induced bronchospasm; mild asthma: use of inhalers only for control of symptoms is acceptable (Persons who have required hospitalization for asthma within the previous 2 years or those who require chronic or frequent oral/parenteral steroids will not be eligible; use of low to medium doses of inhaled steroids; history of coronary artery disease, asymptomatic (NYHA Function Class I), on a stable medical regimen. Persons meeting these criteria must be at least 2 years post-myocardial infarction, cardiac bypass surgery, and/or percutaneous coronary intervention (e.g., angioplasty, stent placement, etc) in order to qualify. Persons with a history of cardiac disease must be under the care of a physician.

Exclusion Criteria:

• Prior history of anthrax or immunization against anthrax
• Known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex
• Pregnancy or plans to become pregnant for the duration of the study and/or not agreeing to exercise adequate birth control from the time of the screening procedures to one month after the last vaccination
• Received experimental products within 30 days prior to study entry
• Plans to receive experimental products within 60 days after study entry
• Received a live vaccine outside this trial within 30 days prior to study entry
• Received an inactivated vaccine outside this trial within 14 days prior to study entry
• Plans to receive a live vaccine outside this trial within 60 days after study entry
• Plans to receive an inactivated vaccine outside this trial within 42 days after study entry
• Received immunosuppressive therapy within 30 days prior to study entry
• Plans to receive immunosuppressive therapy within 60 days after study entry
• Use of cytotoxic therapy in the previous 5 years
• Plans to receive cytotoxic therapy within 60 days after study entry
• Receipt of parenteral immunoglobulin or blood products within three months of study
• Plans to receive parenteral immunoglobulin or blood products within 60 days after study entry
• Active malignancy or history of metastatic or hematologic malignancy
• Any current diabetes
• Cardiovascular disease with a significant likelihood of progression over 5 years, including any person with a history of cardiomyopathy or congestive heart failure
• Moderate to severe asthma, chronic obstructive pulmonary disease, other significant pulmonary disease
• Persons who are using high doses of inhaled steroids
• Clinically recognized hepatic or renal insufficiency
• Inflammatory, vasculitic, or rheumatic disease including systemic lupus erythematosis, polymyalgia rheumatica and rheumatoid arthritis, scleroderma
• Known HIV, hepatitis B or hepatitis C infection
• Other conditions known to produce or be associated with immune suppression
• Neuropathy or other evolving neurologic condition
• Unstable and/or moderate to severe mental illness
• Ongoing drug abuse/dependence (including alcohol)
• Seizure disorder
• In addition to the conditions listed above, moderate or severe illness and/or oral temperature higher than 100.4˚F within 3 days of injection or chronic condition that, in the opinion of the investigator, would render injection unsafe or would interfere with evaluations would be considered a temporary exclusion criterion.

Contacts and Locations

Locations

United States, Alabama

Dr Scott Parker

Birmingham, Alabama, United States

United States, Georgia

Dr. Harry Keyserling

Atlanta, Georgia, United States

United States, Maryland

Dr Janiine Babcock

Silver Spring, Maryland, United States

United States, Minnesota

Dr. Gregory Poland

Rochester, Minnesota, United States

United States, Texas

Dr. Wendy Keitel

Houston, Texas, United States

Sponsors and Collaborators

Centers for Disease Control and Prevention

Walter Reed Army Institute of Research (WRAIR)

Baylor College of Medicine

University of Alabama at Birmingham

Emory University

Mayo Clinic

Investigators

• Principal Investigator: Jennifer Wright, DVM; Centers for Disease Control and Prevention

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. Clin Vaccine Immunol. 2016 Apr 4;23(4):326-38. doi: 10.1128/CVI.00696-15. Print 2016 Apr.

Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039. Epub 2013 Dec 25.

Falola MI, Wiener HW, Wineinger NE, Cutter GR, Kimberly RP, Edberg JC, Arnett DK, Kaslow RA, Tang J, Shrestha S. Genomic copy number variants: evidence for association with antibody response to anthrax vaccine adsorbed. PLoS One. 2013 May 31;8(5):e64813. doi: 10.1371/journal.pone.0064813. Print 2013.

Pajewski NM, Parker SD, Poland GA, Ovsyannikova IG, Song W, Zhang K, McKinney BA, Pankratz VS, Edberg JC, Kimberly RP, Jacobson RM, Tang J, Kaslow RA. The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun. 2011 Sep;12(6):457-65. doi: 10.1038/gene.2011.15. Epub 2011 Mar 3.

Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP; Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 1;300(13):1532-43. doi: 10.1001/jama.300.13.1532. Erratum In: JAMA. 2008 Nov 19;300(19):2252.

• Responsible Party: Centers for Disease Control and Prevention
• ClinicalTrials.gov Identifier: NCT00119067
• Other Study ID Numbers: CDC-NCID-3344
• First Posted: July 13, 2005
• Last Update Posted: February 26, 2014
• Last Verified: September 2012

Keywords provided by Centers for Disease Control and Prevention:

Anthrax; Vaccine; Immunogenicity; Reactogenicity

Additional relevant MeSH terms:

Anthrax; Bacillaceae Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections